Trifas COR (torasemide) tablets 5 mg. №30

Description

Trifas COR (torasemide) tablets 5 mg. №30

Composition

active substance: torasemide;

1 tablet contains torasemide 5 mg;

Excipients: lactose monohydrate, corn starch, colloidal anhydrous silica, magnesium stearate.

Dosage form

Tablets.

Main physical and chemical properties: white, round, slightly biconvex tablets with a notch for distribution on one side.

Pharmacotherapeutic group

Diuretics. Highly active diuretics.
ATX code C0ZS A04.

Pharmacological properties

It is a loop diuretic. In low doses, it has a weak diuretic, saluretic (increase the release of sodium and potassium salts) effect. At a higher dose, increases diuresis (dose-dependent). The main mechanism of the diuretic action is associated with reversible binding to the Na + / 2Cl- / K + cotransporter in the apical section of Henle’s loop, as a result of which renal reabsorption of sodium and chlorine ions is inhibited, the excretion of potassium, magnesium, bicarbonates is stimulated for the second time, and calcium excretion decreases.

Indications

Trifas Cor is prescribed for the treatment of edema and / or effusion caused by cardiac insufficiency.

Contraindications

You cannot assign Trifas Cor:

• with intolerance to the components of the drug;
• with intolerance to sulfonylurea preparations;
• with renal failure with anuria;
• with hepatic coma / precoma;
• with arterial hypotension;
• with hypovolemia;
• with hyponatremia;
• with hypokalemia;
• in acute urinary disorders (for example, due to prostate hypertrophy);
• when breastfeeding;
• children.

Application during pregnancy and lactation

During pregnancy, Trifas Cor is used only for health reasons.
This medicine is not used during breastfeeding.

Method of administration and dosage

Trifas Cor is administered orally (inside) on an empty stomach.
For adults, treatment begins with a single dose of 5 mg (tablet) per day. If the therapeutic effect is insufficient, a single dose is increased to 10 mg. In case of insufficient effectiveness, short-term therapy (up to three days) can be applied using a dose of 20 mg per day.
It is forbidden to exceed the maximum daily dose of 200 mg.
Patients with insufficient liver and / or kidney function need dose adjustment (possibly an increase in the concentration of the active substance in the blood).

Overdose

An overdose of Trifas Cor may be accompanied by increased urine output, electrolyte imbalance, drowsiness, amentive syndrome (confusion, incoherence of speech, chaotic movements), symptomatic arterial hypotension, cardiovascular insufficiency, and digestive disorders.
Overdose treatment: dose reduction or drug withdrawal, fluid and electrolyte replacement (after appropriate control).

Side effects:

• Metabolic disorders: metabolic alkalosis, muscle spasms, hyperuricemia, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, hypokalemia, disturbances in water and electrolyte balance (hypovolemia, hyponatremia, hypokalemia).
• Cardiovascular disorders: thrombosis, arterial hypotension, cerebral / cardiac ischemia, syncope, angina pectoris, cardiac arrhythmias, acute myocardial infarction.
• Digestive disorders: flatulence, loss of appetite, stomach pain, diarrhea, nausea / vomiting, constipation, pancreatitis.
• Urinary disorders: hypercreatininemia, urinary retention, urge to urinate.
• Hepatobiliary disorders: increased blood levels of γ-glutamyl transpeptidase.
• Hematological disorders: thrombocytopenia, erythrocytopenia, leukocytopenia.
• Dermatological disorders: allergic reactions (exanthema, pruritus, photosensitivity).